Compare Amylx Pharmaceuticals Inc (AMLX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Otis Worldwide Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Otis Worldwide Corp trades at $73.33 (market cap $28.05B). The key difference: Otis Worldwide Corp is far larger — about 14.2× Amylx Pharmaceuticals Inc's market cap, and Otis Worldwide Corp pays a 2.33% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | OTIS | |
|---|---|---|
Market Cap | $1.98B | $28.05B |
Sector | Health | Industrials |
52-Week High | $18.70 | $101.07 |
52-Week Low | $7.64 | $69.34 |
Enterprise Value | $1.70B | $35.43B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Otis Worldwide trades at $73.09, up 1.51% today, amid a bearish technical signal despite neutral oscillators. The company reported mixed quarterly earnings, with Q1 2026 missing estimates, but maintains steady revenue growth and a 10.11% net income margin. Recent news highlights strategic modernization projects and a 5% dividend increase, while analyst consensus remains cautiously optimistic with a $94 price target.
The stock presents a value opportunity with a P/E of 19.44 below historical averages, but faces headwinds from China exposure and margin pressure. Upside potential exists if earnings rebound, though high debt and competitive risks warrant caution for investors seeking stable industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
